ASH Conference 2023 explores ways to extend su... - CLL Support
ASH Conference 2023 explores ways to extend survival for those with CLL
You need to be a member of this community to see this post.
6 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Alterations of the immune system caused by CLL B‐cells
Abstract: Here, we review the current understanding of the underlying interplay between the...
New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors
MS-553 is a protein kinase C-beta (PKCß) inhibitor designed to be an alternative treatment option...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
Dated 1st September 2019
In a phase III trial of patients with previously untreated CLL...
del17p CLL? Overall Survival and Progression-Free Survival Are Improved With Ibrutinib
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p...
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
February 2020
A long paper and too much information to be able to summarise in this post but a nice...
Related Posts
Sequential And Combination Treatments With Novel Agents (Oct. 2019)
A new kid on the block? Nemtabrutinib
Revolution of Chronic Lymphocytic LeukemiaTherapy: the Chemo-Free Treatment Paradigm
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial - Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
